Sep. 19, 2024
CARLSBAD, CALIFORNIA — Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that preclinical results with ReSonance (ANP1), the company’s auditory neuronal cell transplant for the treatment of hearing loss, were presented at the 59th Annual Inner Ear Biology Workshop by Ofer Wiser, Ph.D. Senior Scientist, Technological Innovation